We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+59.56%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$2.68B
AUM Growth
+$655M
Cap. Flow
+$121M
Cap. Flow %
4.53%
Top 10 Hldgs %
72.14%
Holding
35
New
8
Increased
6
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$92.6M
2
OCUL icon
Ocular Therapeutix
OCUL
+$28.9M
3
RLMD icon
Relmada Therapeutics
RLMD
+$22.9M
4
TENX icon
Tenax Therapeutics
TENX
+$22.7M
5
ANL
Adlai Nortye
ANL
+$21.5M

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$41.6M
2
UPB
Upstream Bio Inc
UPB
+$31.7M
3
CTMX icon
CytomX Therapeutics
CTMX
+$28.3M
4
ERAS icon
Erasca
ERAS
+$17.4M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$10.1B
$715M 26.68%
8,493,321
– –
ERAS icon
2
Erasca
ERAS
$6.77B
$265M 9.89%
16,382,812
-1,474,271
-8% -$17.4M
ORKA
3
Oruka Therapeutics
ORKA
$5.58B
$203M 7.6%
4,148,428
– –
SYRE icon
4
Spyre Therapeutics
SYRE
$8.61B
$186M 6.94%
3,685,448
– –
KALV
5
DELISTED
KalVista Pharmaceuticals
KALV
$130M 4.86%
6,474,485
-254,500
-4% -$4.1M
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.62B
$99M 3.7%
1,180,000
+180,000
+18% +$10.4M
DMRA
7
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.85B
$93.3M 3.48%
+3,603,595
New +$92.6M
OCUL icon
8
Ocular Therapeutix
OCUL
$1.88B
$87.6M 3.27%
10,346,926
+3,031,379
+41% +$28.9M
COGT icon
9
Cogent Biosciences
COGT
$6.76B
$77M 2.87%
2,000,000
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$2.12B
$75.9M 2.83%
3,882,709
– –
SVRA icon
11
Savara
SVRA
$1.16B
$75M 2.8%
13,740,375
– –
ELVN icon
12
Enliven Therapeutics
ELVN
$3.78B
$67.7M 2.53%
1,726,331
-1,500,000
-46% -$41.6M
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.11B
$54.7M 2.04%
4,319,765
-1,356,465
-24% -$15.4M
VOR icon
14
Vor Biopharma
VOR
$1.06B
$54.3M 2.03%
3,041,719
+1,097,953
+56% +$15.5M
MAZE
15
Maze Therapeutics
MAZE
$1.58B
$47.8M 1.78%
1,602,034
+53,465
+3% +$2.36M
CTMX icon
16
CytomX Therapeutics
CTMX
$725M
$46.9M 1.75%
9,982,124
-5,579,376
-36% -$28.3M
JBIO
17
Jade Biosciences
JBIO
$1.21B
$45.2M 1.69%
3,220,364
– –
DYN icon
18
Dyne Therapeutics
DYN
$3.84B
$39.4M 1.47%
2,173,913
– –
CBIO
19
Crescent Biopharma
CBIO
$565M
$39.2M 1.46%
2,133,576
– –
ZURA icon
20
Zura Bio
ZURA
$513M
$38.3M 1.43%
6,434,990
+1,089,875
+20% +$6.58M
RLMD icon
21
Relmada Therapeutics
RLMD
$525M
$33.7M 1.26%
+4,843,380
New +$22.9M
ENGN icon
22
enGene Therapeutics
ENGN
$124M
$32.5M 1.21%
4,771,414
– –
TENX icon
23
Tenax Therapeutics
TENX
$392M
$26.8M 1%
+1,675,262
New +$22.7M
ANL
24
Adlai Nortye
ANL
$854M
$22.2M 0.83%
+3,212,731
New +$21.5M
IPSC icon
25
Century Therapeutics
IPSC
$388M
$19.7M 0.73%
+8,695,652
New +$18.3M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.66B AUM 14.89% 1-Year Est. Return
TPSF
Texas Permanent School Fund Austin, Texas $2.7B AUM 6.73% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return

VR Adviser's Q1 2026 Portfolio in Review

As of Q1 2026, VR Adviser held 35 positions worth $2.68B, up 32% from $2.02B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

VR Adviser deployed $121M of net new capital in Q1 2026, opening 8 new positions and adding to 6 existing holdings. Its largest new stake was Damora Therapeutics, Inc. Ordinary Shares: 3,603,595 shares worth $93.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Enliven Therapeutics, an estimated $41.6M trimmed.

  • VR Adviser's largest Q1 2026 buy was Damora Therapeutics, Inc. Ordinary Shares: 3,603,595 shares worth $93.3M.
  • VR Adviser added most to Ocular Therapeutix in Q1 2026, an estimated $28.9M increase.
  • VR Adviser's biggest Q1 2026 reduction was Enliven Therapeutics, cutting an estimated $41.6M.
  • VR Adviser fully exited Upstream Bio Inc in Q1 2026, selling an estimated $31.7M.
  • VR Adviser's ten largest holdings make up 72% of its $2.68B portfolio in Q1 2026.
  • VR Adviser opened 8 new positions and closed 2 in Q1 2026.
  • VR Adviser's portfolio value rose 32% quarter-over-quarter to $2.68B.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.